VIP (Vasoactive Intestinal Peptide)

VIP lands at Neutral because it pairs a genuine, well-mapped anti-inflammatory and immune mechanism, and a larger registered-trial footprint than most grey-market peptides, with a disappointing net efficacy record outside one niche use. If you understand that the mechanism is real but the proof is thin for the uses people actually want it for, can source licensed or compliantly compounded material under clinical supervision, and expect maintenance dosing rather than a durable reset, it is a reasonable thing to research carefully. If you expect evidence-backed anti-inflammatory or respiratory results, the honest read is that the best trials do not support it: the two largest respiratory trials missed their primary endpoints, per Youssef 2022 and TESICO 2023, and the one clearly positive randomized result is the niche erectile combination, per Dinsmore 1999. The two biggest real-world frictions are the vasodilation side effects and the compounded sourcing for the off-label uses.

✅ Best for: Researchers who value a real, well-mapped anti-inflammatory and immune mechanism and accept that the human proof is small and biomarker-based. People who can source licensed Invicorp where it is available, or compliantly compounded material under clinical supervision rather than a grey-market vial. Those who expect maintenance dosing and a subtle, indication-specific effect rather than a durable reset. Anyone drawn to a peptide with an unusually large registered-trial footprint who will judge it honestly against the failed flagship trials. Users who understand that the intranasal protocol they read about rests on observational, non-indexed evidence.

❌ Avoid if: You expect proven anti-inflammatory or respiratory results, since the two largest trials missed their primary endpoints, per TESICO 2023. You have low blood pressure, unstable cardiovascular disease, or take other vasodilators, because vasodilation is the core action and effect. You want a durable reset, since VIP clears quickly and is maintenance-dependent. You cannot verify a compounded source, because sterility, identity, and stability are buyer-beware outside the licensed erectile product. You are relying on the intranasal chronic inflammatory response syndrome protocol as evidence-based, since it rests on single-clinic, non-PubMed-indexed reports.